Search

Nanobiotix

Avatud

20.75 12.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.82

Max

21.3

Põhinäitajad

By Trading Economics

Sissetulek

-46M

Müük

-21M

Kasumimarginaal

221.361

Töötajad

108

EBITDA

-44M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+20.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. okt 2025

Turustatistika

By TradingEconomics

Turukapital

893M

Eelmine avamishind

8.1

Eelmine sulgemishind

20.75

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2025, 16:58 UTC

Tulu

BMW Trims 2025 View, Citing Weaker Performance in China

7. okt 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. okt 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. okt 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. okt 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 20:44 UTC

Kuumad aktsiad

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. okt 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. okt 2025, 19:23 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. okt 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. okt 2025, 16:28 UTC

Tulu

BMW to Post Full Quarterly Results, Adjusted Outlook on Nov. 5

7. okt 2025, 16:28 UTC

Tulu

BMW Remains Committed to Share Buyback Program

7. okt 2025, 16:27 UTC

Tulu

BMW: Dividend Payout Ratio Remains Between 30% and 40% of Net Income Attributable to Shareholders

7. okt 2025, 16:27 UTC

Tulu

BMW Sees 2025 FCF in Automotive Segment Above EUR2.5B, Prior Above EUR5B

7. okt 2025, 16:26 UTC

Tulu

BMW Sees Slight Decline in 2025 Group Earnings Before Tax, Prior Forecast on Same Level as 2024

7. okt 2025, 16:25 UTC

Tulu

BMW Sees 2025 RoCE in Automotive Segment Between 8% and 10%, Prior 9% to 13%

7. okt 2025, 16:25 UTC

Tulu

BMW: 2025 Auto EBIT Margin Forecast Range Remains Between 5% to 7%, Lower Part More Likely

7. okt 2025, 16:23 UTC

Tulu

BMW Decided to Reduce Volume Expectations for Chinese Market in 4Q

7. okt 2025, 16:22 UTC

Tulu

BMW: Targeted Volume Growth in China Remained Below Expectations

7. okt 2025, 16:21 UTC

Tulu

BMW Cuts 2025 View

7. okt 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Nanobiotix Prognoos

Hinnasiht

By TipRanks

20.59% tõus

12 kuu keskmine prognoos

Keskmine 20.5 EUR  20.59%

Kõrge 21 EUR

Madal 20 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
help-icon Live chat